

## EDITORIAL ADVISORY BOARD

### *American Continent*

- JULIUS AXELROD—National Institutes of Health, Bethesda, MD  
 MICHAEL R. BOYD—Developmental Therapeutics Program, National Cancer Institute, Executive Plaza North, Rockville, MD  
 EDWARD BRESNICK—Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH  
 D. N. BRINDLEY—Faculty of Medicine, University of Alberta, Edmonton, Canada  
 MICHAEL J. BROWNSTEIN—National Institutes of Health, Bethesda, MD  
 JACK R. COOPER—Yale University School of Medicine, New Haven, CT  
 JAMES K. COWARD—College of Pharmacy, University of Michigan, Ann Arbor, MI  
 IAN CREESE—Center for Molecular and Behavioral Neuroscience, 195 University Avenue, Newark, NJ  
 JOHN W. DALY—National Institutes of Health, Bethesda, MD  
 EKWIN G. ERDŐS—Department of Pharmacology, University of Illinois, College of Medicine, Chicago, IL  
 MARIA ERECINSKA—University of Pennsylvania, Philadelphia, PA  
 RAY W. FULLER—Lilly Research Laboratories, Indianapolis, IN  
 ROBERT C. GALLO—National Institutes of Health, Bethesda, MD  
 JAMES R. GILLETTE—National Institutes of Health, Bethesda, MD  
 ROBERT I. GLAZER—Georgetown University, Washington, DC  
 I. DAVID GOLDMAN—Medical College of Virginia, Richmond, VA  
 THEODORE E. GRAM—1036 Welsh Drive, Rockville, MD  
 M. R. HANLEY—School of Medicine, University of California, Davis, CA  
 G. H. HITCHINGS—Wellcome Research Laboratories, Research Triangle Park, NC  
 LOUIS J. IGNARRO—UCLA School of Medicine, Department of Pharmacology, Los Angeles, CA  
 WILLIAM B. JAKOBY—National Institutes of Health, Bethesda, MD  
 DAVID G. JOHNS—National Institutes of Health, Bethesda, MD  
 HAROLD KALANT—University of Toronto, School of Medicine, Toronto, Ontario, Canada  
 YUTAKA KOBAYASHI—Ko-By Associates, 60 Audubon Road, Wellesley, MA  
 WALTER M. LOVENBERG—Marion Merrell Dow Research Institute, Cincinnati, OH  
 P. N. MAGEE—Temple University School of Medicine, Philadelphia, PA  
 G. J. MANNERING—Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN  
 TAG E. MANSOUR—Department of Pharmacology, Stanford University Medical Center, Stanford, CA  
 PAUL B. MCCAY—Oklahoma Medical Research Foundation, Oklahoma City, OK  
 HERBERT Y. MELTZER—Case Western Reserve University, Cleveland, OH  
 ESTEBAN MEZEY—Johns Hopkins University School of Medicine, Baltimore, MD  
 DANIEL W. NEBERT—Department of Environmental Health, University of Cincinnati, Cincinnati, OH  
 CHARLES A. NICHOL—Glaxo Research Laboratories, Research Triangle Park, NC  
 ROBERT E. PARKS, JR.—Brown University, Providence, RI  
 GABRIEL L. PLAA—University of Montreal, Quebec, Canada  
 EUGENE ROBERTS—City of Hope Medical Center, Duarte, CA  
 JEROME A. ROTH—State University of New York, Medical Center, Buffalo, NY  
 CHARLES O. RUTLEDGE—School of Pharmacy, Purdue University, West Lafayette, IN 47907  
 BORIS TABAKOFF—National Institutes of Health, Bethesda, MD  
 JOHN F. TALLMAN—Yale University, School of Medicine, New Haven, CT  
 SNORRI S.V. THORGEIRSSON—National Institutes of Health, Bethesda, MD  
 DAVID C. U'PRICHARD—ICI Americas Inc., Stuart Pharmaceuticals, Wilmington, DE  
 MARTHA VAUGHAN—National Institutes of Health, Bethesda, MD  
 NORMAN WEINER—Abbott Laboratories, Abbott Park, IL  
 ARNOLD D. WELCH (Chairman)—Frederick Cancer Research Facility of National Cancer Institute, Frederick, MD  
 JOHN R. WILLIAMSON—University of Pennsylvania, Philadelphia, PA

### *European Continent*

- F. M. BELPAIRE—J. F. and C. Heymans Institute of Pharmacology, Rijksuniversiteit, Ghent, Belgium  
 A. G. H. BLAKELEY—Department of Physiology, The University, Leicester, U.K.  
 K. W. BOCK—Institute of Toxicology, Tübingen University, F.R.G.  
 J. CALDWELL—St. Mary's Hospital Medical School, London, U.K.  
 R. A. J. CHALLISS—Department of Pharmacology, University of Leicester, Leicester, U.K.  
 T. A. CONNORS—MRC Toxicology Unit, Carshalton, Surrey, U.K.  
 E. DE CLERCQ—Rega Institute for Medical Research, University of Leuven, Belgium  
 J. FRERE—Institute de Chimie, Université de Liège, Liège, Belgium  
 T. GODFRAND—Université Catholique de Louvain, Belgium  
 R. J. GRYGLEWSKI—School of Medicine, Cracow, Poland  
 J. HAMON—INSERM U288, Neurobiol Cellulaire et Fonctionnelle, Faculté de Médecine Pitie-Salpêtrière, 91 Blvd de l'Hôpital, F-75634 Paris Cédex 14, France  
 J. HANOUNE—INSERM U99, Hôpital Henri Mondor, Creteil, France  
 J. A. HICKMAN—Department of Physiological Sciences, University of Manchester, Manchester, U.K.  
 I. JANKO—Institute of Pharmacology, Czechoslovak Academy of Sciences, Czechoslovakia  
 P. JENNER—Department of Pharmacology, King's College, London SW5 8AF, U.K.  
 H. KAPPUS—Freie Universität Berlin, Germany  
 J. LUNDBERG—Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden  
 G. P. MANNAERTS—Dienst Farmakologie, Campus Gasthuisberg, Onderwijs en Navorsing, Herestraat, 3000 Leuven, Belgium  
 D. MANSUY—Université René Descartes, Laboratoire de Chimie et de Biochimie, Pharmacologiques et Toxicologiques, 45 rue des Saints-Pères, 75270 Paris Cédex 05, France  
 A. E. M. MCLEAN—Department of Clinical Pharmacology, University College Hospital Medical School, London, U.K.  
 C. J. MEADE—Department of Pharmacology, Boehringer Ingelheim KG, D-6507 Ingelheim am Rhein, F.R.G.  
 G. MILLIGAN—Department of Biochemistry, University of Glasgow, Glasgow, U.K.  
 P. MOLDEUS—Department of Toxicology, Karolinska Institute, 104 01 Stockholm 60, Sweden  
 G. J. MULDER—Department of Toxicology, University of Leiden, Sylvius Laboratories, P.O. Box 9503, 2300 RA Leiden, The Netherlands  
 K. J. NETTER—Department of Pharmacology and Toxicology, Philipps University, Marburg, Germany  
 H. NOHL—Institute of Pharmacology and Toxicology, University of Vienna, Vienna, Austria  
 A. J. PAINE—St Bartholomew's Hospital Medical School, London, U.K.  
 B. K. PARK—Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, U.K.  
 D. V. PARKE—Department of Biochemistry, University of Surrey, Guildford, Surrey, U.K.  
 E. REID—Guildford Academic Associates, Guildford, Surrey, U.K.  
 E. REINER—Yugoslav Academy of Sciences and Arts, 4100 Zagreb, Yugoslavia  
 A. G. RENWICK—University of Southampton, Faculty of Medicine, Southampton, U.K.  
 P. J. ROBERTS—Department of Physiology and Pharmacology, Medical and Biological Sciences Building, Southampton, U.K.  
 M. SANDLER—Bernhard Baron Memorial Research Laboratories, Queen Charlotte's Maternity Hospital, London, U.K.  
 H. SIES—Institut für Physiologische Chemie I, Universität Düsseldorf, Düsseldorf, Germany  
 J. SKODA—Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague, Czechoslovakia  
 B. TESTA—Department of Pharmacy, University of Lausanne, Lausanne, Switzerland  
 K. TIPTON—Department of Biochemistry, University of Dublin, Trinity College, Ireland  
 V. ULLRICH—Fakultät für Biologie, Universität Konstanz, Konstanz, Germany  
 P. WALDMEIER—Ciba-Geigy Limited, CH-4002 Basle, Switzerland  
 M. B. H. YODIM—Technion-Israel Institute of Technology, Faculty of Medicine, Department of Pharmacology, Bat Galim, Haifa, Israel

## EDITORIAL ADVISORY BOARD—continued

### *Asia and Pacific Rim*

K. KURIYAMA—Kyoto Prefectural University of Medicine,  
Kyoto, Japan

T. WATABE—Tokyo College of Pharmacy, Tokyo, Japan

---

## AIMS AND SCOPE

BIOCHEMICAL PHARMACOLOGY is an international journal which publishes original research in the form of full-length papers, short communications, rapid communications, invited commentaries and meeting reports. Contributors are asked to note that the Editors will in general accept contributions in English only.

Research with intact animals, cells, subcellular components, enzymes and model systems is acceptable if it defines the mechanism of drug action. Studies concerned with antimicrobial and antiviral agents are welcomed, as well as descriptive mathematical models including those involving computer techniques. The use of drugs to elucidate physiological and behavioural mechanisms in the living organism is also acceptable.

In general, papers which record concentrations of drugs and metabolites in body fluids will not be accepted, unless they define biochemical and biophysical mechanisms. The Editors however reserve the right to publish any papers of major interest in the field. The journal publishes the following types of communication:

(1) **Full-length Papers.** These consist of a body of work presenting original findings relating to the question proposed by the investigators undertaking the research.

(2) **Short Communications.** These consist of an original body of work of narrower scope but of the same quality as the above. By definition, these papers are shorter than full-length manuscripts. The last paragraph of the communication should summarize the findings of the research.

(3) **Rapid Communications.** These promote rapid dissemination of timely and significant observations within the scope of the journal. Manuscripts must be submitted in English and will be judged as appropriate for publication as rapid communications on the basis of their immediate importance. They should be written to emphasize clearly the novel aspects of the research. These criteria will be applied strictly. In order to speed up the publication of rapid communications, authors are encouraged to use the special laysheets available from any of the Regional Editors.

(4) **Commentaries** are short commissioned review articles (3000–5000 words in length). They are designed to be editorial statements on selected topics, and should *not* be exhaustive reviews. Primarily, Commentaries are intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity, or draw attention to relatively neglected fields in which there are both the opportunity and the need for research in biochemical pharmacology. Particularly welcome will be Commentaries in which authors present their personal view on the state of the subject on which they are reporting, and give their view as to where in the near or distant future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas. The Commentary series is edited by Professor C. Norman Gillis.

In order to increase the exchange of information and ideas, the Journal will also publish Comments on a Commentary, in which selected, highly qualified authorities are invited to offer their own observations on Commentary articles, which will be published in the same issue of the Journal, and thus provide some alternative thoughts on important areas of research. For further information see *Biochem Pharmacol* 31, 2568 (1982).

While the final decision on selection of authors for either Commentaries or Comments on a Commentary will be made at the discretion of the editor, suggestions from readers will be welcome. These should be addressed to: Professor C. N. Gillis, Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510.

(5) **Meeting Reports.** The journal is prepared to publish as preliminary communications short, factual two-page summaries of selected papers from small meetings or conferences. The meetings should be those where attendance is by invitation and all papers to be published will be refereed. Organizers who wish to have their meetings published in this way should contact the appropriate Regional Editor.

### **Policy concerning availability of materials**

It is understood that by publishing a paper in *Biochemical Pharmacology* the authors agree to make freely available to colleagues in academic research any of the cells, nucleic acids, antibodies, etc. that were used in the research reported and that are not available from commercial suppliers.

Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7